Q2 26 EPS
$0.22
BEAT +0.92%
Est. $0.22
Q2 26 Revenue
$153.2M
MISS 1.56%
Est. $155.6M
vs S&P Since Q2 26
+2.7%
BEATING MARKET
BVS +3.1% vs S&P +0.4%
Market Reaction
Did BVS Beat Earnings? Q2 2026 Results
Bioventus Inc. Delivered a mixed but largely solid second quarter, nudging past earnings expectations while falling slightly short on revenue, all while disclosing a strategic alternatives review that may prove to be the quarter's defining developmen… Read more Bioventus Inc. Delivered a mixed but largely solid second quarter, nudging past earnings expectations while falling slightly short on revenue, all while disclosing a strategic alternatives review that may prove to be the quarter's defining development. The medical device company posted adjusted EPS of $0.22, edging above the $0.22 consensus estimate by 0.92% and extending its streak of beating EPS estimates to five consecutive quarters. Revenue of $153.21 million grew 3.8% year over year but came in 1.56% below the $155.64 million consensus, pressured by timing shifts in Surgical Solutions capital placements and softer Medicare patient mix in Restorative Therapies. The standout driver was Pain Treatments, where global revenue surged 11.5% to $81.75 million on strong Durolane demand. A $24.60 million deferred tax asset valuation allowance reversal lifted GAAP net income to $33.44 million. Looking ahead, management reaffirmed full-year 2026 guidance of $600 million to $610 million in net sales and adjusted EPS of $0.75 to $0.79, even as an independent committee, advised by Evercore, evaluates strategic alternatives following an unsolicited acquisition proposal.
Key Takeaways
- • Strong volume growth in Durolane hyaluronic acid therapy drove Pain Treatments segment growth of 11.5%
- • Favorable customer mix in Pain Treatments relative to the prior-year period
- • Lower interest expense contributed to adjusted EPS growth
- • Removal of $24.6 million deferred tax asset valuation allowance boosted GAAP net income
BVS Forward Guidance & Outlook
Bioventus reaffirmed its full-year 2026 guidance: net sales of $600 million to $610 million (approximately 6% to 7% growth), adjusted EPS of $0.75 to $0.79, and cash from operations of $84 million to $89 million. The company is also conducting a review of strategic alternatives following receipt of an unsolicited acquisition proposal and multiple other expressions of interest, though no timetable has been set and there is no assurance the review will result in any transaction.
BVS YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
BVS Revenue by Segment
With YoY comparisons, source: SEC Filings
BVS Revenue by Geography
With YoY comparisons, source: SEC Filings
“Bioventus continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the second half of the year. We remain focused on disciplined execution while continuing to invest in our four growth drivers. We believe this compelling combination will accelerate revenue growth, strengthen profitability and earnings power, and drive significant free cash flow.”
— Rob Claypoole, Q2 2026 Earnings Press Release
BVS Earnings Trends
BVS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BVS EPS Trend
Earnings per share: estimate vs actual
BVS Revenue Trend
Quarterly revenue: estimate vs actual
BVS Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $0.22 | $0.22 | +0.92% | $153.2M | -1.56% |
| Q1 26 BEAT | $0.07 | $0.15 | +120.59% | $132.1M | +1.69% |
| Q4 25 BEAT FY | $0.22 | $0.24 | +10.75% | $157.9M | +1.91% |
| FY Full Year | — | $0.68 | — | $568.1M | — |
| Q3 25 BEAT | $0.12 | $0.15 | +30.43% | $138.7M | +0.34% |
| Q2 25 BEAT | $0.20 | $0.21 | +6.76% | $147.7M | +1.23% |
| Q1 25 BEAT | $0.02 | $0.08 | +250.88% | $123.9M | +0.95% |